FluxMPS™ Minimum Essential Medium Eagle (MEM) w/ Earle's salts, NEAA: 1X Liquid

FluxMPS™ Minimum Essential Medium Eagle (MEM) w/ Earle's Salts, NEAA, 1X Liquid

FluxMPS™ MEM with Earle's Salts and Non-Essential Amino Acids (NEAA) is a production-grade, ultra-filtered 1X liquid cell culture medium engineered for microphysiological systems (MPS), organ-on-a-chip (OoC), and microfluidic tissue models. Processed through a proprietary Quadruple-stage filtration system (0.1 µm ×2 + 0.04 µm ×2), it delivers approximately 5× cleaner particulate profile than conventional 0.22 µm-filtered MEM, with endotoxin below 0.05 EU/mL and sub-mycoplasma polishing for ultra-clean, microchannel-safe performance.

• Quadruple-stage nano-filtration: 0.1 µm pre-filter → 0.04 µm fine filter → 0.1 µm sterile filter → 0.04 µm final polish
• Ultra-low particulate: ≥10 µm and ≥25 µm counts per USP <788> Method 2 — microchannel-safe
• Endotoxin < 0.05 EU/mL by USP <85> Limulus Amebocyte Lysate (LAL) assay
• Earle's balanced salt formulation with complete NEAA supplement (Gly, L-Ala, L-Asn, L-Asp, L-Glu, L-Pro, L-Ser) for broader cell line support
• Formulated with Ultrapure Type 1 water (18.2 MΩ·cm, USP <85> compliant)
• ISO Class 5 (Class 100) cleanroom aseptic fill & finish
• pH, glucose concentration, L-glutamine, HEPES, and NEAA composition customizable on request

Engineered where standard MEM fails

Conventional 0.22 µm-filtered MEM retains subvisible particles, mycoplasma-class contaminants, and endotoxin fragments that compromise organ-on-a-chip sensors, clog microfluidic channels, and corrupt metabolic assay signals. FluxMPS™ MEM with Earle's Salts and NEAA eliminates these failure modes through a proprietary four-stage nano-filtration architecture and ISO Class 5 aseptic fill, delivering a microchannel-safe, ultra-clean medium validated at every level where standard basal media fall short.^[1,2]

Quadruple-stage filtration system

FluxMPS™ MEM with Earle's Salts and NEAA is the only ready-to-use 0.04 µm final-filtered MEM on the market. The four-stage cascade achieves an ultra-clean, ultra-low particulate profile that conventional single-pass 0.22 µm filtration cannot replicate, making it the reference standard for MPS, organ-on-a-chip, and precision microfluidic perfusion.

1. 1

   0.1 µmPre-filtration I — Large Particulate Removal

   Removes gross aggregates, large particles, and precipitates that would rapidly blind downstream nano-filters, extending the overall filtration cascade life and maximizing throughput.

2. 2

   0.04 µmPre-filtration II — Fine Particulate & Mycoplasma Barrier

   Retains fine particulates, bacteria, and critically mycoplasma-class organisms (200–300 nm diameter), providing sub-mycoplasma polishing that 0.22 µm filters cannot guarantee.

3. 3

   0.1 µmSterile-filtration I — Second-Pass Redundancy

   Provides a second 0.1 µm barrier as a validated sterility assurance step, eliminating any particles that shed from earlier filter stages and affirming bioburden reduction.

4. 4

   0.04 µmSterile-filtration II — Final Polish

   Ultimate 0.04 µm polish immediately before ISO Class 5 aseptic fill & finish, delivering the lowest achievable particulate count for microfluidic channel safety.

Designed for the most demanding cell culture systems

FluxMPS™ MEM with Earle's Salts and NEAA supports a broad spectrum of research applications, from classical monolayer culture of HeLa and Vero cells to advanced organ-on-a-chip perfusion, iPSC-derived multi-lineage co-cultures, and real-time biosensor-integrated systems. Its ultra-clean purity architecture makes it the medium of choice wherever conventional MEM introduces particle noise or mycoplasma risk.^[4,5]

Automated Bioreactors & Robotics

For high-throughput automated perfusion bioreactors and liquid-handling robotics, an optional 0.01 µm (10 nm) ultra-filtered variant of FluxMPS™ MEM with Earle's Salts and NEAA is available. This next-generation grade achieves near-absolute particulate exclusion for precision perfusion systems where valve and sensor longevity are paramount.

• Total Particulate Exclusion: 10 nm filtration removes nano-aggregates that elude 0.04 µm filters, protecting microvalves and pressure transducers.
• Valve & Sensor Protection: Prevents particle accumulation on solenoid valve seats and optical flow sensors, reducing maintenance intervals in continuous-perfusion rigs.
• Extended Perfusion Stability: Reduced bioburden and particulate load enable multi-week uninterrupted perfusion runs in closed-loop bioreactor systems.

Inquiry Required: The 0.01 µm (10 nm) ultra-filtered grade is a custom/bulk order configuration. Contact support@diagnocine.com to request this grade for your automated system.

Complete specification matrix

All parameters are validated per lot prior to release. Certificate of Analysis (CoA) available upon request at support@diagnocine.com.

Full composition (mg/L)

MEM with Earle’s Salts and NEAA: 36 ingredients verified per lot with CAS numbers. The AMINO ACIDS tab includes both essential amino acids (EAA) and Non-Essential Amino Acids as one combined group per the source composition table.

Manufacturing & compliance standards

Every lot of FluxMPS™ MEM with Earle's Salts and NEAA is manufactured and released under a fully validated ISO 13485:2016 quality management system, with documented micro-batch traceability from raw material receipt through final fill & finish.

How FluxMPS™ MEM + NEAA compares

A head-to-head assessment of FluxMPS™ MEM with Earle's Salts and NEAA against conventional 0.22 µm-filtered MEM alternatives commonly used in cell culture laboratories.

Frequently asked questions

Answers to the most common questions about FluxMPS™ MEM with Earle's Salts and NEAA, its filtration, formulation, and compatibility with advanced culture platforms.

Supporting literature

Curated peer-reviewed references supporting the use of MPS-grade, ultra-filtered media in organ-on-a-chip, microfluidic, and advanced cell culture systems.

1. Huh D, Matthews BD, Mammoto A, et al. Reconstituting organ-level lung functions on a chip. Science. 2010;328(5986):1662–1668.doi:10.1126/science.1188302
2. Bhatt DL, Bhatt AK, Wiegmann B, et al. Organ-on-a-chip platforms for drug testing: bridging the gap between in vitro and in vivo models. Nat Rev Drug Discov. 2022;21:665–687.doi:10.1038/s41573-022-00486-2
3. Ingber DE. Human organs-on-chips for disease modelling, drug development and personalized medicine. Nat Rev Genet. 2022;23:467–491.doi:10.1038/s41576-022-00466-9
4. Mak IW, Evaniew N, Ghert M. Lost in translation: animal models and clinical trials in cancer treatment. Am J Transl Res. 2014;6(2):114–118.PMCID: PMC3966166
5. Young EWK, Beebe DJ. Fundamentals of microfluidic cell culture in controlled microenvironments. Chem Soc Rev. 2010;39(3):1036–1048.doi:10.1039/b909900j
6. Bhatia SN, Ingber DE. Microfluidic organs-on-chips. Nat Biotechnol. 2014;32(8):760–772.doi:10.1038/nbt.2989
7. Zhu J, Shyy JY. Endothelial mechanobiology in arterial disease — the role of shear stress and microfluidic models. J Biomech. 2020;109:109–119.doi:10.1016/j.jbiomech.2020.109898
8. Prantil-Baun R, Novak R, Das D, et al. Physiologically based pharmacokinetic and pharmacodynamic analysis enabled by microfluidically linked organs-on-chips. Annu Rev Pharmacol Toxicol. 2018;58:37–64.doi:10.1146/annurev-pharmtox-010716-104748
9. Eagle H. Amino acid metabolism in mammalian cell cultures. Science. 1959;130(3373):432–437.doi:10.1126/science.130.3373.432
10. Pampaloni F, Reynaud EG, Stelzer EHK. The third dimension bridges the gap between cell culture and live tissue. Nat Rev Mol Cell Biol. 2007;8(10):839–845.doi:10.1038/nrm2236